1-3 of 3
Ken Eguchi
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase 1/2, Open-Label, Dose Escalation, Dose Expansion Study of Menin Inhibitor DSP-5336 in Adult Patients with Acute Leukemia with and without Mixed-Lineage Leukemia (MLL)-Rearrangement (R) or Nucleophosmin 1 (NPM1) Mutation (m)

Naval Daver, Takayuki Ikezoe, Justin Watts, Naoko Hosono, Yoshiaki Ogawa, Yasushi Miyazaki, Harry P. Erba, John Affinito, Emily Brooks, Ken Eguchi, Hongliang Cai, Bo Xu, Jay Stoudemire, Matthew Hitron, Akinobu Watanabe, Philip Komarnitsky, Junichiro Yuda
Journal: Blood
Blood (2022) 140 (Supplement 1): 3371–3372.
https://doi.org/10.1182/blood-2022-167674
Published: 2022
Journal Articles

Phase 1/2, Open-Label, Dose Escalation, Dose Expansion Study of Menin Inhibitor DSP-5336 in Adult Patients (pts) with Acute Leukemia with and without Mixed-Lineage Leukemia ( MLL )-Rearrangement or Nucleophosmin 1 ( NPM1 ) Mutation

Naval Daver, John Affinito, Hongliang Cai, Hanna Dobrowolska, Edward Dow, Ken Eguchi, Gregory Song, Jay Stoudemire, Akinobu Watanbe, Philip Komarnitsky
Journal: Blood
Blood (2021) 138 (Supplement 1): 4431.
https://doi.org/10.1182/blood-2021-147856
Published: 2021
Journal Articles

Preclinical Evaluation of a Novel Orally Bioavailable Menin-MLL Interaction Inhibitor, DSP-5336, for the Treatment of Acute Leukemia Patients with MLL -Rearrangement or NPM1 Mutation

Ken Eguchi, Takafumi Shimizu, Daiki Kato, Yudai Furuta, Seiji Kamioka, Hitoshi Ban, Setsuko Ymamoto, Akihiko Yokoyama, Issay Kitabayashi
Journal: Blood
Blood (2021) 138 (Supplement 1): 3339.
https://doi.org/10.1182/blood-2021-152050
Published: 2021